(DIM) Sartorius Stedim Biotech - Ratings and Ratios
Exchange: PA • Country: France • Currency: EUR • Type: Common Stock • ISIN: FR0013154002
DIM EPS (Earnings per Share)
DIM Revenue
DIM: Instruments, Consumables, Separation, Purification, Systems, Software
Sartorius Stedim Biotech SA is a leading global supplier of innovative technologies and services to the biopharmaceutical industry, providing a comprehensive range of products and solutions that cater to the complex needs of its customers, from cell line development to bioprocessing and quality control.
The companys extensive product portfolio includes cell culture media, bioreactors, and purification systems, as well as advanced technologies such as biolayer interferometry and surface plasmon resonance, which enable its customers to develop and manufacture high-quality biopharmaceuticals efficiently and cost-effectively. Sartorius Stedim Biotech SA serves a diverse customer base, including manufacturers of medications, vaccines, and food, as well as research and development laboratories.
With a strong track record of innovation and a commitment to delivering high-quality products and services, Sartorius Stedim Biotech SA is well-positioned to benefit from the growing demand for biopharmaceuticals and the increasing complexity of bioprocessing. The companys robust product pipeline and strategic investments in R&D are expected to drive long-term growth and expansion.
Analyzing the technical data, the stocks current price of 189.60 is below its 20-day SMA of 197.46, indicating a potential buying opportunity. The stocks ATR of 5.16, representing 2.72% of the current price, suggests moderate volatility. Considering the fundamental data, the companys high P/E ratio of 90.40 and forward P/E of 43.67 indicate high growth expectations. With a market capitalization of 18.8 billion EUR and a relatively low RoE of 5.19, the stocks valuation appears stretched.
Based on the technical and fundamental data, a forecast for Sartorius Stedim Biotech SA is that the stock may experience a short-term correction due to its current oversold condition, potentially rebounding towards its 20-day SMA. However, the high valuation multiples and moderate volatility suggest that the stocks long-term performance will be driven by the companys ability to deliver on its growth expectations and expand its market share in the biopharmaceutical industry. A potential price target could be 210-220, representing a 10-15% upside from current levels.
Additional Sources for DIM Stock
DIM Stock Overview
| Market Cap in USD | 21,760m |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception |
DIM Stock Ratings
| Growth Rating | -10.5 |
| Fundamental | 2.58 |
| Dividend Rating | 45.2 |
| Rel. Strength | 22.4 |
| Analysts | - |
| Fair Price Momentum | 184.38 EUR |
| Fair Price DCF | 128.69 EUR |
DIM Dividends
| Dividend Yield 12m | 0.36% |
| Yield on Cost 5y | 0.33% |
| Annual Growth 5y | 15.21% |
| Payout Consistency | 83.8% |
| Payout Ratio | 32.7% |
DIM Growth Ratios
| Growth Correlation 3m | 30.8% |
| Growth Correlation 12m | 66.9% |
| Growth Correlation 5y | -73.3% |
| CAGR 5y | -0.86% |
| CAGR/Max DD 5y | -0.01 |
| Sharpe Ratio 12m | 0.51 |
| Alpha | 19.41 |
| Beta | 0.532 |
| Volatility | 40.05% |
| Current Volume | 46.7k |
| Average Volume 20d | 49.2k |
As of June 16, 2025, the stock is trading at EUR 199.05 with a total of 46,694 shares traded.
Over the past week, the price has changed by +2.55%, over one month by +0.45%, over three months by -0.20% and over the past year by +16.17%.
Neither. Based on ValueRay´s Fundamental Analyses, Sartorius Stedim Biotech is currently (June 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 2.58 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DIM is around 184.38 EUR . This means that DIM is currently overvalued and has a potential downside of -7.37%.
Sartorius Stedim Biotech has no consensus analysts rating.
According to our own proprietary Forecast Model, DIM Sartorius Stedim Biotech will be worth about 203.1 in June 2026. The stock is currently trading at 199.05. This means that the stock has a potential upside of +2.05%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 242 | 21.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 203.1 | 2% |